400或800毫升细菌计数粪菌移植治疗复发性肝性脑病的疗效与安全性比较:中国多中心前瞻性随机对照试验
本研究为多中心前瞻性随机对照试验,计划从中国31家医院入组100例复发性肝性脑病患者,按1:1随机分配至800毫升或400毫升总细菌计数粪菌移植组,评估两种剂量在24周和48周时的疗效与安全性,包括死亡率和生活质量。若任一或两种剂量安全有效,将填补复发性肝性脑病管理的空白。
要点
- 复发性肝性脑病指6个月内发生两次或以上发作。
- 试验比较800毫升与400毫升总细菌计数粪菌移植的疗效与安全性。
- 主要评估24周和48周时死亡率与生活质量等结局。
核心结论
- 若任一或两种剂量的粪菌移植被证明对复发性肝性脑病安全有效,并能改善24周和48周的生活质量与生存,该试验将填补复发性肝性脑病管理的重要空白,具有创新性和临床意义。
研究设计与样本
- 多中心、前瞻性、随机对照试验,计划从中国31家医院入组100例符合条件的患者。
- 参与者按1:1比例随机分配至高剂量组(800毫升总细菌计数)或低剂量组(400毫升总细菌计数)。
- 主要目标是评估两种剂量在24周和48周时对死亡率、生活质量等结局的疗效与安全性。
- 试验注册号:ClinicalTrials.gov NCT05669651,注册日期2022年12月29日;中国临床试验注册中心 ChiCTR2200067135,注册日期2022年12月27日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatic encephalopathy (HE) represents a critical complications of end-stage liver disease, serving as an independent predictor of mortality among patients with cirrhosis. Despite effective treatment with rifaximin, some patients with HE still progress to recurrent episodes, posing a significant therapeutic challenge. Recurrent HE is defined as experiencing two or more episodes within a 6-month period. Previous research has suggested that FMT may emerge as a promising treatment for recurrent HE. However, there remains a critical need to explore the optimal dosage. This trial aims to abscess the efficacy and safety of two FMT dosages: 800 ml or 400 ml total bacterial count, including mortality and quality of life. METHODS: This multicenter, prospective, randomized controlled trial will enroll 100 eligible patients from 31 hospitals in China. Participants will be randomly assigned in a 1:1 ratio to either the high-dose group (800 ml total bacterial count) or the low-dose group (400 ml total bacterial count). The primary objective is to assess the efficacy and safety of both dosages on outcomes at 24 and 48 weeks, including mortality and quality of life. DISCUSSION: If either or both dosages of FMT demonstrate safe and effective treatment of recurrent HE, leading to improve quality of life and survival at 24 and 48 weeks, this trial would address a significant gap in the management of recurrent HE, carrying innovative and clinically significant implications. TRIAL REGISTRATION: NCT05669651 on ClinicalTrials.gov. Registered on 29 December 2022. CHiCTR2200067135 on China Registered Clinical Trial Registration Center. Registered on 27 December 2022.
引用
- Zou P, Bi Y, Tong Z, et al. Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in China. Trials. 2024. PMID: 39605077. doi:10.1186/s13063-024-08578-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。